February 14, 2018 09:50 AM ESTUpdated 10:02 AM
News Briefing

Post-con­spir­a­cy claims, Arc­turus los­es an­oth­er ex­ec­u­tive amid board putsch; Gates Foun­da­tion hands $6.5M to No­var­tis for in­fec­tious di­ar­rhea treat­ment

John Carroll

Editor & Founder

→ Lit­tle Arc­turus $ARCT is go­ing through a dra­mat­ic shake­up this month. Short­ly af­ter news that its founder and CEO Joseph Payne was boot­ed from …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

The End­points 2024 win­ners and losers list: Who was up and who was down in bio­phar­ma

Up­dat­ed: No­vo’s 23% weight loss with Ca­griSe­ma falls short of high ex­pec­ta­tions, new tri­al planned

FDA ap­proves Hu­ma­cyte’s lab-grown blood ves­sels in mile­stone for re­gen­er­a­tive med­i­cine

Ac­cel­er­at­ed ap­proval brings Pfiz­er's BRAF in­hibitor to first-line pa­tients

Sofinno­va out­lines $550M fund af­ter IPOs and M&A deals

FDA ap­proves Io­n­is’ treat­ment for a rare meta­bol­ic dis­or­der

A service from the Financial Times